Drug Patents Expiring in 2040

1. List of Airduo Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11344685

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Mar, 2040

(17 years from now)

US11439777 TEVA PHARM Drug delivery device with electronics
May, 2040

(17 years from now)

US11464923 TEVA PHARM Inhaler system
Jun, 2040

(17 years from now)

US11173259 TEVA PHARM Drug delivery device with electronics and power management
Jul, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
M Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

2. List of Ameluz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11235169 BIOFRONTERA Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device
Oct, 2040

(17 years from now)

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 10 May, 2016

Treatment: Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminating the treatment area with narrowband red light

Dosage: GEL;TOPICAL

More Information on Dosage

3. List of Armonair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11344685

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Mar, 2040

(17 years from now)

US11439777 TEVA PHARM Drug delivery device with electronics
May, 2040

(17 years from now)

US11464923 TEVA PHARM Inhaler system
Jun, 2040

(17 years from now)

US11173259 TEVA PHARM Drug delivery device with electronics and power management
Jul, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

4. List of Auvelity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940124 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(16 years from now)

US10780064 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(16 years from now)

US10966942 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(16 years from now)

US10925842 AXSOME Bupropion as a modulator of drug activity
Jan, 2040

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

5. List of Emerphed drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241400 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(17 years from now)

US11478436 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(17 years from now)

US11090278 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(17 years from now)

US11464752 NEXUS PHARMS Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
May, 2040

(17 years from now)

Drugs and Companies using EPHEDRINE SULFATE ingredient

Market Authorisation Date: 17 April, 2020

Treatment: Use of ephedrine sulfate for treating hypotension

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of EMERPHED before it's patent expiration?
More Information on Dosage

6. List of Ephedrine Sulfate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869845 ENDO VENTURES Ephedrine compositions and methods
Jan, 2040

(16 years from now)

Drugs and Companies using EPHEDRINE SULFATE ingredient

Market Authorisation Date: 16 October, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

7. List of Eprontia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11433046 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(17 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 05 November, 2021

Treatment: Indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age and older; Indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; Indicated for the preventive treatment of migraine in patients 12 years and older

Dosage: SOLUTION;ORAL

How can I launch a generic of EPRONTIA before it's patent expiration?
More Information on Dosage

8. List of Epsolay drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10945987 GALDERMA LABS LP Method for providing early onset of action in the treatment of rosacea
Feb, 2040

(17 years from now)

US10933046 GALDERMA LABS LP Method for treatment of rosacea in patients aged 65 years and older
Feb, 2040

(17 years from now)

US11426378 GALDERMA LABS LP Method for long-term treatment of rosacea
Aug, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older; Topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

9. List of Farxiga drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
M Feb 22, 2022
New Indication (I) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's patent expiration?
More Information on Dosage

10. List of Fyarro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11497737 AADI NA
Oct, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Nov 22, 2024

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 22 November, 2021

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

11. List of Hetlioz Lq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11202770 VANDA PHARMS INC Liquid tasimelteon formulations and methods of use thereof
Dec, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

12. List of Ingrezza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940141 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's patent expiration?
More Information on Dosage

13. List of Livmarli drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11229647 MIRUM Methods for treating cholestasis
Feb, 2040

(17 years from now)

US11497745 MIRUM NA
Feb, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2026
Orphan Drug Exclusivity (ODE) Sep 29, 2028

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

More Information on Dosage

14. List of Lumakras drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11236091 AMGEN INC Solid state forms
May, 2040

(17 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426404 AMGEN INC Dosing of KRAS inhibitor for treatment of cancers
Aug, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026
Orphan Drug Exclusivity (ODE) May 28, 2028

Drugs and Companies using SOTORASIB ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage

15. List of Mycapssa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141457 AMRYT Oral octreotide therapy and contraceptive methods
Dec, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jun 26, 2023

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

16. List of Proair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439777 TEVA BRANDED PHARM Drug delivery device with electronics
May, 2040

(17 years from now)

US11464923 TEVA BRANDED PHARM Inhaler system
Jun, 2040

(17 years from now)

US11173259 TEVA BRANDED PHARM Drug delivery device with electronics and power management
Jul, 2040

(17 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

17. List of Qdolo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103452 ATHENA Tramadol hydrochloride solution
Sep, 2040

(17 years from now)

Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Dosage: SOLUTION;ORAL

More Information on Dosage

18. List of Qinlock drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10966966 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11266635 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11426390 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11433056 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11344536 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11185535 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(17 years from now)

US11395818 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 15, 2025
Orphan Drug Exclusivity (ODE) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib; Treatment of gastrointestinal stromal tumors in patients suffering from palmer-planter erythrodysesthesia syndrome; Treatment of gastrointestinal stromal tumors in patients being treated concurrently with a cyp3a4 inhibitor; Method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily; Treatment of gastrointestinal stromal tumors in patients suffering from hypertension

Dosage: TABLET;ORAL

More Information on Dosage

19. List of Recorlev drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278547 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(17 years from now)

US11020393 STRONGBRIDGE Methods of treating disease with levoketoconazole
Mar, 2040

(17 years from now)

Drugs and Companies using LEVOKETOCONAZOLE ingredient

Market Authorisation Date: 30 December, 2021

Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage of metformin as needed

Dosage: TABLET;ORAL

More Information on Dosage

20. List of Scemblix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11407735 NOVARTIS Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
May, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 29, 2026
Orphan Drug Exclusivity (ODE) Oct 29, 2028

Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient

NCE-1 date: October, 2025

Market Authorisation Date: 29 October, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

21. List of Sunosi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940133 JAZZ Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment

Dosage: TABLET;ORAL

More Information on Dosage

22. List of Tymlos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11255842 RADIUS HEALTH INC Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog
Jan, 2040

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
M Sep 20, 2024

Drugs and Companies using ABALOPARATIDE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Use for detecting neutralizing antibodies

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of TYMLOS before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

List of large molecules

1. List of Elyea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
USD961376 REGENERON PHARMACEUTICALS, INC. Packaging
Aug, 2040

(17 years from now)

US11439758 REGENERON PHARMACEUTICALS, INC. Devices and methods for precision dose delivery
Aug, 2040

(17 years from now)

US11433186 REGENERON PHARMACEUTICALS, INC. Devices and methods for precision dose delivery
Aug, 2040

(17 years from now)

USD961377 REGENERON PHARMACEUTICALS, INC. Packaging
Aug, 2040

(17 years from now)

US11472861 REGENERON PHARMACEUTICALS, INC. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Aug, 2040

(17 years from now)

US11459374 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(17 years from now)

US11459373 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(17 years from now)

Ingredients: AFLIBERCEPT

2. List of Eylea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US11053280 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(17 years from now)

US11306135 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(17 years from now)

US11299532 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(17 years from now)

US11186625 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(17 years from now)

US11174283 REGENERON PHARMACEUTICALS, INC. Anti-VEGF protein compositions and methods for producing the same
Aug, 2040

(17 years from now)

US11104715 REGENERON PHARMACEUTICALS, INC. Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Aug, 2040

(17 years from now)

Ingredients: AFLIBERCEPT

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in